www.nytimes.com
Open in
urlscan Pro
151.101.1.164
Public Scan
URL:
https://www.nytimes.com/2023/11/11/well/live/ozempic-wegovy-heart-disease-obesity.html
Submission: On January 16 via manual from US — Scanned from US
Submission: On January 16 via manual from US — Scanned from US
Form analysis 2 forms found in the DOM
POST https://nytimes.app.goo.gl/?link=https://www.nytimes.com/2023/11/11/well/live/ozempic-wegovy-heart-disease-obesity.html&apn=com.nytimes.android&amv=9837&ibi=com.nytimes.NYTimes&isi=284862083
<form method="post" action="https://nytimes.app.goo.gl/?link=https://www.nytimes.com/2023/11/11/well/live/ozempic-wegovy-heart-disease-obesity.html&apn=com.nytimes.android&amv=9837&ibi=com.nytimes.NYTimes&isi=284862083"
data-testid="MagicLinkForm" style="visibility: hidden;"><input name="client_id" type="hidden" value="web.fwk.vi"><input name="redirect_uri" type="hidden"
value="https://nytimes.app.goo.gl/?link=https://www.nytimes.com/2023/11/11/well/live/ozempic-wegovy-heart-disease-obesity.html&apn=com.nytimes.android&amv=9837&ibi=com.nytimes.NYTimes&isi=284862083"><input name="response_type"
type="hidden" value="code"><input name="state" type="hidden" value="no-state"><input name="scope" type="hidden" value="default"></form>POST https://nytimes.app.goo.gl/?link=https://www.nytimes.com/2023/11/11/well/live/ozempic-wegovy-heart-disease-obesity.html&apn=com.nytimes.android&amv=9837&ibi=com.nytimes.NYTimes&isi=284862083
<form method="post" action="https://nytimes.app.goo.gl/?link=https://www.nytimes.com/2023/11/11/well/live/ozempic-wegovy-heart-disease-obesity.html&apn=com.nytimes.android&amv=9837&ibi=com.nytimes.NYTimes&isi=284862083"
data-testid="MagicLinkForm" style="visibility: hidden;"><input name="client_id" type="hidden" value="web.fwk.vi"><input name="redirect_uri" type="hidden"
value="https://nytimes.app.goo.gl/?link=https://www.nytimes.com/2023/11/11/well/live/ozempic-wegovy-heart-disease-obesity.html&apn=com.nytimes.android&amv=9837&ibi=com.nytimes.NYTimes&isi=284862083"><input name="response_type"
type="hidden" value="code"><input name="state" type="hidden" value="no-state"><input name="scope" type="hidden" value="default"></form>Text Content
Skip to contentSkip to site index
Search & Section Navigation
Section Navigation
SEARCH
Live
SUBSCRIBE FOR $1/WEEKLog in
Tuesday, January 16, 2024
Today’s Paper
SUBSCRIBE FOR $1/WEEK
WEIGHT LOSS DRUGS
* Ozempic: What to Know
* Zepbound: What to Know
* What the Drugs Really Cost
* What if You Stop?
* Risks for Older Users
* U.S.
SECTIONS
* U.S.
* Politics
* New York
* California
* Education
* Health
* Obituaries
* Science
* Climate
* Sports
* Business
* Tech
* The Upshot
* The Magazine
U.S. POLITICS
* 2024 Elections
* Supreme Court
* Congress
* Biden Administration
TOP STORIES
* Trump Investigations
* The Eric Adams Administration
* Abortion in the U.S.
NEWSLETTERS
* The Morning
Make sense of the day’s news and ideas.
* The Upshot
Analysis that explains politics, policy and everyday life.
See all newsletters
PODCASTS
* The Daily
The biggest stories of our time, in 20 minutes a day.
* The Run-Up
On the campaign trail with Astead Herndon.
See all podcasts
* World
SECTIONS
* World
* Africa
* Americas
* Asia
* Australia
* Canada
* Europe
* Middle East
* Science
* Climate
* Health
* Obituaries
TOP STORIES
* Israel-Hamas War
* Russia-Ukraine War
NEWSLETTERS
* Morning Briefing: Europe
Get what you need to know to start your day.
* The Interpreter
Original analysis on the week’s biggest global stories.
* Australia Letter
News, features and opinion for readers in the region.
* Canada Letter
Backstories and analysis from our Canadian correspondents.
See all newsletters
* Business
SECTIONS
* Business
* Tech
* Economy
* Media
* Finance and Markets
* DealBook
* Personal Tech
* Energy Transition
* Your Money
TOP STORIES
* U.S. Economy
* Stock Market
* Artificial Intelligence
NEWSLETTERS
* DealBook
The most crucial business and policy news you need to know.
See all newsletters
PODCASTS
* Hard Fork
Our tech journalists help you make sense of the rapidly changing tech
world.
See all podcasts
* Arts
SECTIONS
* Today's Arts
* Books
* Best Sellers
* Dance
* Movies
* Music
* Television
* Theater
* Pop Culture
* T Magazine
* Visual Arts
RECOMMENDATIONS
* Best of 2023
* Award Season
* Critic’s Picks
* What to Read
* What to Watch
* What to Listen To
* 5 Minutes to Make You Love Music
NEWSLETTERS
* Read Like the Wind
Book recommendations from our critics.
* Watching
Streaming TV and movie recommendations.
See all newsletters
PODCASTS
* Book Review
The podcast that takes you inside the literary world.
* Popcast
Pop music news, new songs and albums, and artists of note.
See all podcasts
* Lifestyle
SECTIONS
* Lifestyle
* Well
* Travel
* Style
* Real Estate
* Food
* Fashion
* Love
* Your Money
* Personal Tech
* T Magazine
COLUMNS
* Modern Love
* The Hunt
* Social Q’s
* The Ethicist
WELL
* Eat
* Move
* Mind
* Family
* Live
* Ask Well
NEWSLETTERS
* Open Thread
The latest news on what we wear, by our chief fashion critic.
* Love Letter
Real stories of relationship highs, lows and woes.
See all newsletters
PODCASTS
* Modern Love
The complicated love lives of real people.
See all podcasts
* Opinion
SECTIONS
* Opinion
* Guest Essays
* Editorials
* Op-Docs
* Videos
* Letters
TOPICS
* Politics
* World
* Business
* Tech
* Climate
* Health
* Culture
COLUMNISTS
* Charles M. Blow
* Jamelle Bouie
* David Brooks
* Gail Collins
* Ross Douthat
* Maureen Dowd
* David French
* Thomas L. Friedman
* Michelle Goldberg
* Ezra Klein
* Nicholas Kristof
* Paul Krugman
* Carlos Lozada
* Tressie McMillan Cottom
* Pamela Paul
* Lydia Polgreen
* Bret Stephens
* Zeynep Tufekci
PODCASTS
* Matter of Opinion
Thoughts, aloud. With Michelle Cottle, Ross Douthat, Carlos Lozada and
Lydia Polgreen.
* The Ezra Klein Show
Discussions of ideas that matter, plus book recommendations.
See all podcasts
* Audio
AUDIO
Podcasts and narrated articles covering news, tech, culture and more.
Download the Audio app on iOS.
LISTEN
* The Headlines
* The Daily
* Hard Fork
* The Ezra Klein Show
* Matter of Opinion
* Serial Productions
* The Book Review Podcast
* Modern Love
* The Run-Up
* Popcast
* Reporter Reads
* The Sunday Read
See all audio
FEATURED
* The Headlines
Your morning listen. Top stories, in 5 minutes.
* The Kids of Rutherford County
A series about how one county illegally jailed children.
* Reporter Reads
Recent articles read by the reporters behind them.
NEWSLETTERS
* Audio
Our editors share their favorite listens from the New York Times Audio
app.
See all newsletters
Audio is included in an All Access subscription. Learn more.
* Games
GAMES
Word games, logic puzzles and crosswords, including an extensive archive.
PLAY
* Spelling Bee
* The Mini Crossword
* Wordle
* The Crossword
* Vertex
* Connections
* Sudoku
* Letter Boxed
* Tiles
COMMUNITY
* Spelling Bee Forum
* Wordplay Column
* Wordle Review
* Submit a Crossword
* Meet Our Crossword Constructors
* Mini to Maestro
* Wordlebot
NEWSLETTERS
* Gameplay
Puzzles, brain teasers, solving tips and more.
See all newsletters
Games is included in an All Access subscription. Learn more.
* Cooking
COOKING
Recipes, advice and inspiration for everyday cooking, special occasions and
more.
RECIPES
* Easy
* Dinner
* Quick
* Healthy
* Breakfast
* Vegetarian
* Vegan
* Chicken
* Pasta
* Dessert
EDITORS' PICKS
* Soups and Stews
* Easy Weeknight
* Newest Recipes
* One-Pot Meals
* Slow Cooker Recipes
* Comfort Food
* Party Recipes
NEWSLETTERS
* The Cooking Newsletter
Culinary inspiration from Sam Sifton and Melissa Clark.
* The Veggie
Delicious vegetarian recipes and tips from Tanya Sichynsky.
* Five Weeknight Dishes
Dinner ideas for busy people from Emily Weinstein.
See all newsletters
Cooking is included in an All Access subscription. Learn more.
* Wirecutter
WIRECUTTER
Reviews and recommendations for thousands of products.
REVIEWS
* Kitchen
* Tech
* Sleep
* Appliances
* Home and Garden
* Moving
* Travel
* Gifts
* Deals
* Baby and Kid
* Health and Fitness
THE BEST...
* Air Purifier
* Electric Toothbrush
* Pressure Washer
* Cordless Stick Vacuum
* Office Chair
* Robot Vacuum
NEWSLETTERS
* The Recommendation
The best independent reviews, expert advice and intensively researched
deals.
* Clean Everything
Step-by-step advice on how to keep everything in your home squeaky clean.
See all newsletters
Wirecutter is included in an All Access subscription. Learn more.
* The Athletic
THE ATHLETIC
Personalized coverage of your sports teams and leagues.
LEAGUES
* NFL
* MLB
* NBA
* Premier League
* NCAAF
* NCAAM
* NHL
* NCAAW
* MLS
* Formula 1
* NWSL
* Golf
TOP STORIES
* Must-Read Stories
* NFL Standings
* MLB Free Agency
NEWSLETTERS
* The Pulse
Delivering the top stories in sports, Sunday to Friday.
* The Windup
The biggest stories in baseball, by Levi Weaver with Ken Rosenthal.
* The Bounce
Essential NBA news from Zach Harper and Shams Charania.
* Full Time
The biggest women's soccer stories, from Emily Olsen, Meg Linehan & Steph
Yang
The Athletic is included in an All Access subscription. Learn more.
Weight Loss Drugs
* Ozempic: What to Know
* Zepbound: What to Know
* What the Drugs Really Cost
* What if You Stop?
* Risks for Older Users
Advertisement
SKIP ADVERTISEMENT
WEIGHT LOSS DRUGS
* Ozempic: What to Know
* Zepbound: What to Know
* What the Drugs Really Cost
* What if You Stop?
* Risks for Older Users
Supported by
SKIP ADVERTISEMENT
WEGOVY IS SHOWN TO REDUCE RISK OF HEART ATTACKS AND STROKES IN SOME PATIENTS
The results of a large clinical trial suggest the obesity medication could also
change the landscape of cardiovascular care.
* Share full article
*
*
* 155
* Read in app
Credit...Illustration by Andrei Cojocaru; Photographs by Getty Images
By Dani Blum
Reporting from the American Heart Association Scientific Sessions in
Philadelphia
Nov. 11, 2023
Sign up for the Well newsletter, for Times subscribers only. Essential news and
guidance to live your healthiest life. Try it for 4 weeks.
A pivotal new study suggests that the weight loss drug Wegovy cut the risk of
heart attack, stroke or death from cardiovascular issues by 20 percent among
overweight or obese people with heart disease — a striking benefit that could
change the standard of care for these patients.
“We’ve just identified a new best practice,” said Dr. Clyde Yancy, chief of the
division of cardiology at Northwestern Medicine, who was not involved with the
study. But the research also raises questions about exactly how the drug helps
the heart — through weight loss itself, or other mechanisms — and whether it can
be as effective in a real-world setting, with a more diverse group of patients
than those included in the trial.
Still, the results of the study, presented Saturday in a standing-room only
session at an American Heart Association meeting in Philadelphia, are a turning
point for the sought-after new class of obesity and diabetes drugs that also
includes Ozempic and the newly approved Zepbound. Drug companies see potential
for the medicines that extends far beyond obesity. Proving that the drugs not
only treat diabetes and help patients lose weight, but also can lower the risk
of other serious diseases linked with obesity, could further drive demand — and
pressure insurance companies to cover them at a broader scale.
Subscribe to The Times to read as many articles as you like.
A correction was made on
Nov. 12, 2023
:
An earlier version of this article misstated the name of an author on the study.
It is Dr. Ildiko Lingvay, not Idiko.
--------------------------------------------------------------------------------
When we learn of a mistake, we acknowledge it with a correction. If you spot an
error, please let us know at nytnews@nytimes.com.Learn more
Dani Blum is a reporter for Well. More about Dani Blum
A version of this article appears in print on Nov. 12, 2023, Section A, Page 16
of the New York edition with the headline: Weight Loss Drug Wegovy Is Seen to
Limit Heart Risks. Order Reprints | Today’s Paper | Subscribe
Read 155 Comments
* Share full article
*
*
* 155
* Read in app
Advertisement
SKIP ADVERTISEMENT
COMMENTS 155
Wegovy Is Shown to Reduce Risk of Heart Attacks and Strokes in Some PatientsSkip
to Comments
Share your thoughts.
The Times needs your voice. We welcome your on-topic commentary, criticism and
expertise. Comments are moderated for civility.
SITE INDEX
SITE INFORMATION NAVIGATION
* © 2024 The New York Times Company
* NYTCo
* Contact Us
* Accessibility
* Work with us
* Advertise
* T Brand Studio
* Your Ad Choices
* Privacy Policy
* Terms of Service
* Terms of Sale
* Site Map
* Canada
* International
* Help
* Subscriptions
Support independent journalism with a subscription. Already a subscriber? Log
in.
--------------------------------------------------------------------------------
Enjoy unlimited access to all of The Times.
Includes news, games, recipes and more.
Welcome offer
$6.25 $1/week
Billed as $4 every 4 weeks for your first 6 months.
Cancel or pause anytime.
PayPal
OR
Check out with card
All Access includes news, plus Games, Cooking, Audio, Wirecutter and The
Athletic.
--------------------------------------------------------------------------------
Offer for a New York Times All Access subscription; current subscribers not
eligible. Subscription excludes print edition. Some games may be available
without a subscription. Your payment method will automatically be charged in
advance the introductory rate of $4.00 every 4 weeks for 6 months, and after 6
months the standard rate of $25.00 every 4 weeks. Your subscription will
continue until you cancel. Cancellation takes effect at the end of your current
billing period. Taxes may apply. Offer terms are subject to change.
--------------------------------------------------------------------------------
©2024 The New York Times Company
Help Feedback